Visceral Leishmaniasis
Mostrando 37-48 de 597 artigos, teses e dissertações.
-
37. Improving the reference standard for the diagnosis of canine visceral leishmaniasis: a challenge for current and future tests
BACKGROUND Studies aimed at validating canine visceral leishmaniasis diagnostic tests present heterogeneous results regarding test accuracy, partly due to divergences in reference standards used and different infection evolution periods in animals. OBJECTIVE This study aimed to evaluate the accuracy of the rapid test-dual path platform (TR-DPP) (Biomangu
Mem. Inst. Oswaldo Cruz. Publicado em: 31/01/2019
-
38. Leishmaniose visceral e sua relação com fatores climáticos e ambientais no Estado do Tocantins, Brasil, 2007 a 2014
Resumo: A leishmaniose visceral (LV) pode ser influenciada por fatores climáticos e ambientais. Tocantins é o estado com mais incidência no Brasil, contribuindo para o aumento dos casos na macrorregião Norte. Este estudo tem objetivo de identificar a correlação entre a taxa de incidência de LV e fatores climáticos e ambientais, nos municípios do Est
Cad. Saúde Pública. Publicado em: 10/01/2019
-
39. First report of an autochthonous human visceral leishmaniasis in a child from the South of Minas Gerais State, Brazil
ABSTRACT American visceral leishmaniasis (VL) is a vector-borne disease transmitted by some species of phlebotomine sandflies from the genus Lutzomyia. This neglected tropical zoonosis shows increasing urbanization process, since the end of the 1980s. After the emergence of foci of the disease in urban areas, VL has assumed an important role in public health
Rev. Inst. Med. trop. S. Paulo. Publicado em: 20/12/2018
-
40. Second-generation pterocarpanquinones: synthesis and antileishmanial activity
Abstract Background: Despite the development of new therapies for leishmaniasis, among the 200 countries or territories reporting to the WHO, 87 were identified as endemic for Tegumentary Leishmaniasis and 75 as endemic for Visceral Leishmaniasis. The identification of antileishmanial drug candidates is essential to fill the drug discovery pipeline for leis
J. Venom. Anim. Toxins incl. Trop. Dis. Publicado em: 17/12/2018
-
41. Activity of the antiarrhythmic drug amiodarone against Leishmania (L.) infantum: an in vitro and in vivo approach
Abstract Background: Considering the high toxicity and limited therapies available for treating visceral leishmaniasis (VL), the drug repositioning approach represents a faster way to deliver new therapies to the market. Methods: In this study, we described for the first time the activity of a potent antiarrhythmic, amiodarone (AMD), against L. (L.)infantu
J. Venom. Anim. Toxins incl. Trop. Dis. Publicado em: 29/11/2018
-
42. Renal dysfunction in Leishmaniasis and Chagas disease coinfection: a case report
ABSTRACT Visceral leishmaniasis (VL) is an endemic parasitic disease frequently found in Northeast Brazil and may cause acute kidney injury (AKI) and glomerulonephritis. After appropriate treatment, renal function recovery may occur. We describe the rare case of a patient with VL, who developed severe AKI requiring dialysis and was subsequently diagnosed wit
Rev. Inst. Med. trop. S. Paulo. Publicado em: 14/11/2018
-
43. Validation of the Dual-path Platform chromatographic immunoassay (DPP® CVL rapid test) for the serodiagnosis of canine visceral leishmaniasis
BACKGROUND Visceral leishmaniasis is a major public health challenge in South America, and dogs are its main urban reservoir. OBJECTIVE Validation of the canine Dual-path Platform immunoassay for canine visceral leishmaniasis (DPP® CVL) for a sample set composed of 1446 dogs from different Brazilian endemic areas. METHODS A well-defined reference standard b
Mem. Inst. Oswaldo Cruz. Publicado em: 01/11/2018
-
44. Presence of Lutzomyia longipalpis and Nyssomyia whitmani in Entre Rios, Argentina
ABSTRACT The objective of this study was to evaluate the presence of Lutzomyia longipalpis in the Argentine city of Concordia, in the province of Entre Rios, without record of this species despite previous samplings, but with canine cases of visceral leishmaniasis and Lu. longipalpis reports both, from Northern Argentine localities and from the city of Salto
Rev. Inst. Med. trop. S. Paulo. Publicado em: 22/10/2018
-
45. Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications
A pivotal strategy to decrease the risk of visceral leishmaniasis in humans is to control the infection and disease progression in dogs, the domestic reservoir of Leishmania infantum (L. chagasi). Immunotherapy is a viable approach to treat sick dogs because cell-mediated immunity is the principal defense mechanism against L. infantum. Domperidone is an immu
Mem. Inst. Oswaldo Cruz. Publicado em: 18/10/2018
-
46. Neolignans isolated from twigs of Nectandra leucantha Ness & Mart (Lauraceae) displayed in vitro antileishmanial activity
Abstract Background: The therapeutic arsenal for the treatment of Leishmaniasis is limited and includes toxic compounds (antimonials, amphotericin B, pentamidine and miltefosine). Given these aspects, the search for new compounds based on floristic biodiversity is crucial. In the present work, we report the isolation, characterization and antileishmanial ac
J. Venom. Anim. Toxins incl. Trop. Dis. Publicado em: 18/10/2018
-
47. Potential role of zinc in the visceromegaly regression and recovery of hematological parameters during treatment of visceral leishmaniasis in children from an endemic area
ABSTRACT Leishmaniasis is a disease complex with various clinical symptoms caused by different species of parasites of the genus Leishmania. The visceral form of the disease, characterized by severe symptoms is fatal, if not treated. The high toxicity of current antileishmanial drugs and the need for long-term treatment make the therapy complicated, especial
Rev. Inst. Med. trop. S. Paulo. Publicado em: 13/09/2018
-
48. Evaluation of a new brand of immunochromatographic test for visceral leishmaniasis in Brazil made available from 2018
ABSTRACT Immunochromatographic tests based on the recombinant antigen K39 represent a major advance in diagnosing visceral leishmaniasis (VL) in recent years. Some performance variations are expected and have occurred in the use of several commercial rapid tests, especially in different geographical settings. This is the first evaluation in the Americas of t
Rev. Inst. Med. trop. S. Paulo. Publicado em: 13/09/2018